Weaver Consulting Group’s GSK GSK Stock Holding History

Weaver Consulting Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-360	Closed	-$17K	–	443
2020 Q3	$17K	Hold	360	–	–	0.01%	437
2020 Q2	$18K	Hold	360	–	–	0.01%	402
2020 Q1	$17K	Hold	360	–	–	0.01%	352
2019 Q4	$19K	Hold	360	–	–	0.01%	370
2019 Q3	$19K	Hold	360	–	–	0.01%	358
2019 Q2	$18K	Hold	360	–	–	0.01%	352
2019 Q1	$18K	Buy	+360	New	+$18K	0.01%	767

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Weaver Consulting Group's GSK Position: Q4 2020 in Review

Weaver Consulting Group sold out of GSK (GSK) in Q4 2020, closing a stake of 360 shares — an estimated $17K sold.

Weaver Consulting Group first reported a position in GSK in Q1 2019 and held it in 7 quarters. The position peaked at $19K in Q4 2019. 818 funds tracked by Wall St. Rank hold GSK as of Q4 2020.

Weaver Consulting Group reported no remaining GSK position as of Q4 2020 after selling out during the quarter.
Weaver Consulting Group sold 360 GSK shares in Q4 2020, an estimated $17K.
Weaver Consulting Group first reported a position in GSK in Q1 2019 and held it in 7 quarters.
Weaver Consulting Group's GSK position peaked at $19K in Q4 2019.
818 funds tracked by Wall St. Rank held GSK as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.